PNPLA3 and metabolic dysfunction-associated steatotic liver disease: These findings indicate that alogliptin (and other DPP-4 inhibitors) can affect liver function in NAFLD patients proportionally with the extent of improvement in their HbA1c levels, and these effects are influenced by rs738409 genetic polymorphism in PNPLA3.